Finance

Lists
RXRX:NASDAQ
Recursion Pharmaceuticals Inc
US$ ४.१२
+१.२३%
(+०.०५०) 1D
US$ ४.१२
+०.१२% (+०.००५०)
After hours
Closed: अक्टोबर २, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXRX...
Open
US$ ४.१८
High
US$ ४.२७
Low
US$ ४.०१
Mkt. cap
२.२१ अरब
Avg. vol.
१.९३ करोड
Volume
१.८८ करोड
52-wk high
US$ ७.१८
52-wk low
US$ २.७७
EPS
-US$ १.०४
Beta
१.०४
Shares outstanding
५३.५३ करोड
No. of employees
६००
Open
US$ ४.१८
High
US$ ४.२७
Low
US$ ४.०१
Mkt. cap
२.२१ अरब
Avg. vol.
१.९३ करोड
Volume
१.८८ करोड
52-wk high
US$ ७.१८
52-wk low
US$ २.७७
EPS
-US$ १.०४
Beta
१.०४
Shares outstanding
५३.५३ करोड
No. of employees
६००
News stories
From web sources and news partners
About Recursion Pharmaceuticals Inc
CEONajat Khan
Employees६००
Founded२०१३
Headquartersसाल्ट लेक सिटी, युटा, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to RXRX in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months.
Highest
Current US$ ४.१२
US$ ८.०० (+९४.१७%)
Average
US$ ६.६५ (+६१.४१%)
Lowest
US$ ५.३० (+२८.६४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Hold
Maintained
-
-
09/21/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
US$ ५.३०
+२८.६%
08/17/2026
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/05/2026
Gil Blum
Needham
Buy
Maintained
US$ ८.००
+९४.२%
08/05/2026
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ ०.२५ / -US$ ०.२३
-६.८४%miss
Revenue / Est. (USD)
७६.७० लाख / १.२० करोड
-३५.८९%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
५१.७५ लाख
३.५५ करोड
६४.७२ लाख
७६.७० लाख
Cost of goods sold
१३.५७ करोड
११.०२ करोड
१०.०४ करोड
१०.११ करोड
Cost of revenue
१३.५७ करोड
११.०२ करोड
१०.०४ करोड
१०.११ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४.१६ करोड
४.२२ करोड
३.४६ करोड
४.१५ करोड
Operating expense
४.१६ करोड
४.२२ करोड
३.४६ करोड
४.१५ करोड
Total operating expenses
१७.७४ करोड
१५.२४ करोड
१३.५० करोड
१४.२६ करोड
Operating income
-१७.२२ करोड
-११.६८ करोड
-१२.८५ करोड
-१३.५० करोड
Other non operating income
५२.४५ लाख
-६०.२६ लाख
७.८४ लाख
-१०.३५ लाख
EBT including unusual items
-१६.२२ करोड
-१०.८१ करोड
-१२.२१ करोड
-१३.१० करोड
EBT excluding unusual items
-१६.२२ करोड
-११.६६ करोड
-१२.२१ करोड
-१३.१० करोड
Income tax expense
३.०० हजार
२०.०० हजार
-४६.०४ लाख
-१.०० हजार
Effective tax rate
-
-०.०२%
३.७७%
-
Other operating expenses
-
-
-
-
Net income
-१६.२३ करोड
-१०.८१ करोड
-११.७५ करोड
-१३.१० करोड
Net profit margin
-३,१३५.३२%
-३०४.२४%
-१,८१५.५७%
-१,७०८.०२%
Earnings per share
-०.३६
-०.२१
-०.२२
-०.२५
Interest and investment income
५५.४० लाख
६२.५८ लाख
५९.६३ लाख
५३.०६ लाख
Interest expense
-८.३३ लाख
-
-३.५० लाख
-३.०९ लाख
Net interest expenses
४७.०७ लाख
६२.५८ लाख
५६.१३ लाख
४९.९७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१५.१२ करोड
-९.७४ करोड
-१०.८८ करोड
-११.६८ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू